A combination of α-1-antichymotrypsin (AACT), thrombospondin-1 (THBS1), and haptoglobin (HPT) outperformed CA 19−9 in distinguishing pancreatic cancer from normal controls (AUC = 0.95), patients with diabetes (AUC = 0.89), pancreatic cysts (AUC = 0.82), and chronic pancreatitis (AUC = 0.90). This evidence concerns the gene HP and familial pancreatic carcinoma.